Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn if CS-505 is safe and effective for slowing down or
possibly reversing the buildup of tissue, cells and fatty deposits (plaque) in the blood
vessels of the heart (coronary artery atherosclerosis).